Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. Phase III study of local ...
May 11, 2012 (Philadelphia, Pennsylvania) — Intramuscular depot aripiprazole is a safe and tolerable option for long-term maintenance treatment of schizophrenia, according to several presentations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results